International

MPox: First Batch Of Shots Reaches Congo, But How Much Of Help Is It? The Trickle-Down Vaccine Economy

The European Union donated the 1,00,000 doses of the JYNNEOS vaccine, manufactured by the Danish com🐼pany Bavarian Nordic. While adequate mpox vaccine doses are available, high costs and regulatory hurdܫles according to experts have prevented the jabs from reaching the countries in central Africa.

Mpox outbreak in Africa
Mpox outbreak in Africa Photo: AP
info_icon

Three weeks after the World Health Organisation (WHO) declared mpox outbreaks in African countries a global emergency, the first batch containing 1,00,000 doses of mpox vaccine arrived in Congo's capitalꦦ on Thursday, the countr🌊y's authorities said.

The European Union donated the doses of the JYNNEOS vaccine, manufactured by the Danish company Bavarian Nordic. Anothe♒r batch of 1,00,000 vaccines are expected to be delivered on Saturday, Congolese authorities said.

According to Congo's Health Minister Roger Kamba, UNICEF is going to be in charge of the vaccination campaign in the most impacted provinces. Howev💞er, further details on the initiation of the vaccination are yet to be disclosed.

In August, Nigeria became the first African country to receive a batch of 10,000 mpox vaccines donated by t𒐪he🦹 United States.

Mpox: The global health emergency

Mpox had been spreading mostly undetected for years in Africa before the disease promꩲpted the 2022 outbreak in more than 70 countries. The global health watchdog recently declared mpox outbreaks in African countries a global emergency.

“What we are witnessing in Africa now is different f🎃rom the global outbreak in 2022", Dr. Dimie Ogoina, the chair of WHO's mpox emergency committee said.

While earlier that outbreak was primarily focused on gay and bisexual men, mpox is now being spread via sexual transmission as well as through close contact among children, pregnant women, and otཧher vulnerable groups.

Positive cases recorded in 19 countries

As per the latest data from the Afr𓃲ican CDC, a total of 15 countries in the continent have reported Mpox cases including Burundi, Cameroon, Central African Republic, Democratic Republic of the Congo, Ghana, Republic of the Congo (Brazzaville), Ivory Coast, Kenya, Mozambique, Nigeria, Rwanda, South Africa, Uganda, Gabon and Liber♐ia.

Apart from these, Sierra Leone and Malawi are testing their 📖suspec🅠ted cases of Mpox.

Outside Africa, Mpox cases have been detected in Pakistan, Thailand, Sweden, Philippine𝐆s whil🅷e Singapore and Malaysia are also monitoring suspected mpox cases.

JYNNEOS, LC16: The Mpox killers

Ideally, traditional smallpox vaccines have the potency to provide protection against mpox. However, in Africa, these vaccines are not allowed since the 1980s following the global eradication of smallpox which makes the younger generations more susceptible to inf✱ections.

In the wake of a global mpox outbreak in 2022, the wealthier countries are using more rec♊ent vaccines with fewer side effects. The vaccines include the MVA-BN jab developed by Danish manufacturer Bavarian Nordic, also known by its trade names 'JYNNEOS' in the US and 'Imvanex' in Europe, and Japan’s LC16 vaccine. 

Only the LC16 jab is currently approved f𒊎or useও in children.  

According to the Centreꦓ for Disease Control and Prevention (CDC), JYNNEOS is a third-generation v💟accine based on a live, attenuated orthopoxvirus, Modified Vaccinia Ankara (MVA).

CDC further explained that MVA is a live virus that does not replicate efficiently in humans. It is fully licensed in the U.S. for sub𓄧cutaneous administration in individuals 18 years of age and older.

High costs, regulatory issues: The challenges for Africa

According to the Africa CDC's estimation, 10 million doses are needed across the continent to fight the current outbreaks, with Congo being the country most in need. Mercy Muthee Laker, the Congo representative for the Red Cr🌱oss and Red Crescent aid organisation, the doses promised by the West “were quite few compared to the need that we see on the ground.”

According to WHO spokesperson Tarik Jasarevic, the producer of MVA-BN, Bavarian Nordic has the capacity to manufacture 10 million doses by the end of 2025 and can already supply up to two millio🍰n doses this year.

While adequate vaccine doses are availab🅰le, high costs and regulatory hurdles according to expeꩲrts have prevented the jabs from reaching the countries in central Africa.

The Western partners of Africa including the European Union and the United States, have promised delivery of about 3,80,000 doses⛦ of mpox vaccines. However, numbers suggest that this is still less than 15 percent of the 3 million doses authorities have said are needed to end the mpox outbreak♉s in Congo only

Trickle-down Vaccine Economy: The wall between rich and poor

In line with the 'trickle-down' theor♚y of economics, following the 2022 outbreaks, wealthy countries stockpiled the new vaccines to protect their own populations, while only a trickle of doses reached Africa.

According to thꦅe experts, it would likely be weeks before any vaccines are administered considering ꧃the shortcomings in financial resources and logistical planning infrastructure needed to initiate the vaccination drive.

Beacon of hope: Mpox can be stopped, says WHO

Despite declaring a global health emergency, WHO recently said that the ongoing Mpox outbreak in Africa could be stopped in the next six months, adding th🌞at the agency'𒊎s first shipment of vaccines should arrive in Congo within days.

"With the governments' leadership and close cooperation between partnersജ, we believe we can stop these outbreaks in the next six months," WHO Director-General Tedros Adha𝓰nom Ghebreyesus said during a press briefing.